US$ 25.02
dpp 4 inhibitor glp 1 agonist GLP-1 Receptor Agonists Have better Outcomes Than DPP4 Inhibitors in T2D patients & CKD fig2.gif
Description
Neuroprotection of Exendin-4 by enhanced autophagy in a Parkinsonian Rat Model of alpha-Synucleinopathy

It is marketed there under the brand name Lirasen

The authors also suggest a second potential pathway independent of GLP-1 for some of the cardiovascular effects

Non-HDL cholesterol and apolipoprotein B may also show modest improvements, which better reflect atherogenic lipoprotein burden

Ahmed IA

PMID: 60 SontamTChenHRamanJChenAChoSWTarboxM
